Drugs / PCV13i
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT07017777 | Nov 2025 → Feb 2027 expected | pneumococcal infection | CanSino Biologics Inc. | Recruiting | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-07-21 | CanSino Biologics Inc. | CanSinoBIO Signs PCV13i LOI with Pakistani Partner to Expand Vaccine Collaboration in South Asia cansinotech.com ↗ |
| 2025-09-29 | CanSino Biologics Inc. | CanSinoBIO Expands Innovative Vaccine Impact with Domestic Launch of iPneucia® (PCV13i) and International Shipment of Menhycia®(MCV4) cansinotech.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PCV13i | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07017777 ↗ |
| Modality | Vaccine | “experimental vaccine” NCT07017777 ↗ |
| Route | Intramuscular | “Intramuscular Injection, 0.5ml” NCT07017777 ↗ |